Effectiveness, safety and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in HIV-1 infected adult patients in routine clinical practice-6 months results of the BICSTaR cohort

被引：0
|
作者：
Esser, S. [1 ]
Jessen, H. [2 ]
Schneider, J. [3 ]
Schellberg, S. [4 ]
Stellbrink, H-J [5 ]
Waizmann, M. [6 ]
Hillenbrand, H. [7 ]
Bilbao, P. [8 ]
Schreiber, S. [9 ]
Thorpe, D. [8 ]
Ramroth, H. [8 ]
Haubrich, R. [10 ]
Heinzkill, M. [9 ]
机构：
[1] Univ Hosp Essen, Clin Dermatol, Dept Venerol, Essen, Germany
[2] Praxis Jessen Kollegen, Berlin, Germany
[3] Tech Univ Munich, Sch Med, Univ Hosp Rechts Del Isar, Dept Med 2, Munich, Germany
[4] Novopraxis Berlin GbR, Berlin, Germany
[5] ICH Study Ctr, Hamburg, Germany
[6] Praxis Waizmann, Leipzig, Germany
[7] MVZ Praxis City Ost, Berlin, Germany
[8] Gilead Sci Europe Ltd, Uxbridge, Middx, England
[9] Gilead Sci GmbH, Munich, Germany
[10] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
来源：
HIV MEDICINE | 2019年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
PE2/16
引用
收藏
页码：61 / 61
页数：1
相关论文
共 50 条
  • [1] Effectiveness, safety and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adult patients living with HIV-1 in routine clinical practice: 6-month results of the BICSTaR cohort
    Esser, S.
    Jessen, H.
    Schneider, J.
    Schellberg, S.
    Stellbrink, H. J.
    Waizmann, M.
    Hillenbrand, H.
    Bilbao, P.
    Schreiber, S.
    Thorpe, D.
    Ramroth, H.
    Haubrich, R.
    Robinson, C.
    Heinzkill, M.
    HIV MEDICINE, 2020, 21 : 17 - 17
  • [2] Comparing effectiveness and tolerability of emtricitabine/tenofovir alafenamide (F/TAF) with emtricitabine/tenofovir disoproxil fumarate (F/TDF) in HIV-1 infected adult patients in routine clinical practice: a cross cohort analysis
    Esser, S.
    Stellbrink, H-J
    Heiken, H.
    Meynard, J-L
    Thorpe, D.
    Schreiber, S.
    Heinzkill, M.
    Sahali, S.
    Ramroth, H.
    Haubrich, R.
    HIV MEDICINE, 2019, 20 : 67 - 68
  • [3] Effectiveness, safety, and economic impact of the bictegravir/emtricitabine/tenofovir alafenamide regimen in real clinical practice cohort of HIV-1 infected adult patients
    Gutierrez-Lorenzo, Marta
    Rubio-Calvo, Daniel
    Urda-Romacho, Joaquin
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2021, 34 (04) : 315 - 319
  • [4] Patient-reported outcomes (PROs) after 1 year of routine clinical practice with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people living with HIV (PLWH): the BICSTaR cohort
    Knechten, H.
    Milinkovic, A.
    Stephan, C. C.
    Brunetta, J.
    Trottier, B.
    Bonnet, F.
    Duvivier, C.
    Welzen, B. V.
    Mack, F.
    Tossonian, H.
    Thorpe, D.
    Cornejo, A. T.
    Marongiu, A.
    Curbelo, R.
    HIV MEDICINE, 2021, 22 : 31 - 32
  • [5] Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) shows high efficacy in clinical study participants infected with HIV-1 subtype F
    Acosta, R.
    Andreatta, K.
    D'Antoni, M.
    Collins, S.
    Martin, H.
    White, K.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 106 - 106
  • [6] Patient-reported outcomes after 1 year of routine clinical practice with bictegravir/emtricitabine/tenofovir alafenamide in people living with HIV: the BICSTaR cohort
    Knechten, Heribert
    Stephan, Christoph
    Waizmann, Michael
    Brunetta, Jason
    Trottier, Benoit
    Duvivier, Claudine
    van Welzen, Berend
    Mack, Frank
    Tossonian, Harout
    Thorpe, David
    Cornejo, Almudena Torres
    Marongiu, Andrea
    Curbelo, Rafael
    INFECTION, 2021, 49 (SUPPL 1) : S17 - S17
  • [7] Effectiveness and tolerability of the bictegravir/emtricitabine/tenofovir alafenamide regimen in a cohort of HIV-1 infected treatment experienced adult patients: an observational retrospective single-centre study
    Ceccarelli, M.
    Ricciardetto, M.
    Bellocchi, B.
    Todaro, L.
    Boscia, V.
    Campanella, A.
    Nunnari, G.
    Cacopardo, B.
    Celesia, B.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 104 - 104
  • [8] Bictegravir/emtricitabine/tenofovir alafenamide in clinical practice for people with HIV: final 24-month effectiveness and safety outcomes in key populations in the observational BICSTaR cohort
    Trottier, Benoit
    Yang, Chia-Jui
    Watanabe, Dai
    Marchetti, Giulia
    Elbirt, Daniel
    De Barra, Eoghan
    Gunduz, Alper
    Lee, Sun Hee
    Vogelmann, Roger
    Robineau, Olivier
    Choy, Chiaw Yee
    Berrevoets, Marvin
    Uriel, Alison
    Thorpe, David
    Heinzkill, Marion
    Marongiu, Andrea
    Ramroth, Johanna
    D'Amato, Lisa
    Mallolas, Josep
    HIV RESEARCH & CLINICAL PRACTICE, 2025, 26 (01)
  • [9] Effectiveness, safety, and patient-reported outcomes of bictegravir/emtricitabine/tenofovir alafenamide in routine clinical care in Italy: 12-Month results from the BICSTaR cohort
    Antinori, Andrea
    Marchetti, Giulia
    Esposito, Vincenzo
    Rusconi, Stefano
    Canetti, Diana
    Quiros-Roldan, Eugenia
    Candelaresi, Bianca
    Saracino, Annalisa
    Andreoni, Massimo
    Marongiu, Andrea
    Cassidy, Tali
    Thorpe, David
    Albini, Laura
    Caldera, Roberto
    Forcina, Gabriele
    Di Perri, Giovanni
    INTERNATIONAL JOURNAL OF STD & AIDS, 2025, 36 (04) : 309 - 318
  • [10] Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve and treatment-experienced people with HIV: 12-month virologic effectiveness and safety outcomes in the BICSTaR Japan cohort
    Yokomaku, Yoshiyuki
    Teruya, Katsuji
    Watanabe, Dai
    Endo, Tomoyuki
    Minami, Rumi
    Taguchi, Nao
    Cassidy, Tali
    Marongiu, Andrea
    Thorpe, David
    Shirasaka, Takuma
    Oka, Shinichi
    PLOS ONE, 2025, 20 (01):
12345